Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

NCT03528408 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Ocular Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Suthee Rapisuwon

Collaborators

[object Object]